HER2: An emerging target in colorectal cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Van Cutsem, 2009, Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann Oncol, 20, 61, 10.1093/annonc/mdp130
Poon, 1989, Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma, J Clin Oncol, 7, 1407, 10.1200/JCO.1989.7.10.1407
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol 1992;10:896-903.
Labianca, 1991, Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer), Ann Oncol, 2, 673, 10.1093/oxfordjournals.annonc.a058047
Venook, 2017, Effect of First-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with kRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial, JAMA, 317, 2392, 10.1001/jama.2017.7105
Heinemann, 2014, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol, 15, 1065, 10.1016/S1470-2045(14)70330-4
Venook, 2016, Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance), J Clin Oncolo, 34, 10.1200/JCO.2016.34.15_suppl.3504
Salem, 2017, Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers, Oncotarget, 8, 86356, 10.18632/oncotarget.21169
Loree, 2018, Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes, Clin Cancer Res, 24, 1062, 10.1158/1078-0432.CCR-17-2484
Stintzing, 2017, Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes, Eur J Cancer, 84, 69, 10.1016/j.ejca.2017.07.016
Sartore-Bianchi, 2009, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies, Cancer Res, 69, 1851, 10.1158/0008-5472.CAN-08-2466
Sorich, 2015, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials, Ann Oncol, 26, 13, 10.1093/annonc/mdu378
Yang, 2013, Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis, Int J Cancer, 133, 1914, 10.1002/ijc.28153
Di Nicolantonio, 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, J Clin Oncol, 26, 5705, 10.1200/JCO.2008.18.0786
Yonesaka, 2011, Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab, Sci Transl Med, 3, 10.1126/scitranslmed.3002442
Mohan, 2014, Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing, PLoS Genet, 10, 10.1371/journal.pgen.1004271
Bertotti, 2011, A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, Cancer Discov, 1, 508, 10.1158/2159-8290.CD-11-0109
Takegawa, 2017, HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy, Clin Colorectal Cancer, 16, 247, 10.1016/j.clcc.2017.03.001
Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106
Gusterson, 1992, Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group, J Clin Oncol, 10, 1049, 10.1200/JCO.1992.10.7.1049
Gravalos, 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 19, 1523, 10.1093/annonc/mdn169
Begnami, 2011, Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome, J Clin Oncol, 29, 3030, 10.1200/JCO.2010.33.6313
Valtorta, 2015, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Mod Pathol, 28, 1481, 10.1038/modpathol.2015.98
Conradi, 2013, Frequency of HER-2 positivity in rectal cancer and prognosis, Am J Surg Pathol, 37, 522, 10.1097/PAS.0b013e318272ff4d
Marx, 2010, Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers, Hum Pathol, 41, 1577, 10.1016/j.humpath.2010.02.018
Seo, 2014, HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression, PLoS One, 9, e98528, 10.1371/journal.pone.0098528
Park, 2007, HER-2/neu overexpression is an independent prognostic factor in colorectal cancer, Int J Colorectal Dis, 22, 491, 10.1007/s00384-006-0192-8
Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152
Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X
Richman, 2016, HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials, J Pathol, 238, 562, 10.1002/path.4679
Kavuri, 2015, HER2 activating mutations are targets for colorectal cancer treatment, Cancer Discov, 5, 832, 10.1158/2159-8290.CD-14-1211
2012, Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252
Martin, 2013, HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients, Br J Cancer, 108, 668, 10.1038/bjc.2013.4
Sartore-Bianchi, 2016, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 738, 10.1016/S1470-2045(16)00150-9
Siena S, Sartore-Bianchi A, Trusolino L, et al. Final results of the HERACLES trial in HER2-amplified colorectal cancer. Presented at 2017 AACR Annual Meeting, April 1-5 abstract CT005, 2017.
Raghav, 2016, HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer, J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.3517
Khurana, 2014, Heregulin in breast cancer: old story, new paradigm, Curr Pharm Des, 20, 4874, 10.2174/1381612819666131125151519
Breuleux, 2007, Role of heregulin in human cancer, Cell Mol Life Sci, 64, 2358, 10.1007/s00018-007-7120-0
Heitzer, 2013, Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing, Genome Med, 5, 30, 10.1186/gm434
Ben-David, 2017, Patient-derived xenografts undergo mouse-specific tumor evolution, Nat Genet, 49, 1567, 10.1038/ng.3967
Harbeck, 2013, HER2 dimerization inhibitor pertuzumab - mode of action and clinical data in breast cancer, Breast Care (Basel), 8, 49, 10.1159/000346837
Isakoff, 2011, Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer, J Clin Oncol, 29, 351, 10.1200/JCO.2010.31.6679
Clark, 2003, Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzamab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy, Proc Am Soc Oncol, 22
Ramanathan, 2004, Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial, Cancer Invest, 22, 858, 10.1081/CNV-200039645
Bekaii-Saab, 2009, A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies, Mol Cancer Ther, 8, 2983, 10.1158/1535-7163.MCT-09-0820
Price, 2014, Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study, Lancet Oncol, 15, 569, 10.1016/S1470-2045(14)70118-4
Mayer, 2015, Randomized trial of TAS-102 for refractory metastatic colorectal cancer, N Engl J Med, 372, 1909, 10.1056/NEJMoa1414325
Grothey, 2013, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 381, 303, 10.1016/S0140-6736(12)61900-X
Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol, 18, 1182, 10.1016/S1470-2045(17)30422-9
Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733
Siena, 2016, HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial, J Clin Oncol, 34, 10.1200/jco.2016.34.4_suppl.tps774
Hurwitz, 2017, Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway, J Clin Oncol, 35, 10.1200/JCO.2017.35.4_suppl.676
Moulder, 2017, Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC), Clin Cancer Res, 23, 3529, 10.1158/1078-0432.CCR-16-1496
Strickler, 2017, A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER), J Clin Oncol, 35, 10.1200/JCO.2017.35.15_suppl.TPS3624
Missiaglia, 2014, Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features, Ann Oncol, 25, 1995, 10.1093/annonc/mdu275
Ahmed, 2010, HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors, Clin Cancer Res, 16, 10.1158/1078-0432.CCR-09-1322
Sun, 2014, Construction and evaluation of a novel humanized HER2-specific chimeric receptor, Breast Cancer Res, 16, R61, 10.1186/bcr3674
Luo, 2016, Bifunctional alphaHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer, Cell Res, 26, 850, 10.1038/cr.2016.81
Ahmed, 2009, Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression, Mol Ther, 17, 1779, 10.1038/mt.2009.133